R&D

LENTIVIRAL VECTOR R&D

Lentisoma

VIVEbiotech´s development strategy is focused on:

  • Developing scalable, regulatory compliant and more cost-effective lentiviral vectors.
  • Enhancing the safety profile of viral vectors.

For this reason, VIVEbiotech is working in the following areas:

  • Continued optimization/adaptation of USP and DSP processes focusing on increasing titre and enhancing purity.
  • The development of improved producer cell lines.
  • New pseudotyping strategies.
  • Lentisoma: a worldwide patented technology (WO 2015/078999 A1) consisting of an episomal non-integrative stable lentiviral vector that provides a lasting, stable, consistent expression of the transgene in dividing and non-dividing cells.

Once our development strategy has been concluded, our final aim is transferring these improvements to the GMP CDMO services for our customers´ benefit.

Contact us

Mikeletegi Pasealekua 81, San Sebastián 20009, Gipuzkoa (SPAIN)

JOIN US

linkedinb